Respiratory syncytial virus (RSV) is the major cause of hospitalization for children under two years of age. RSV vaccines are currently unavailable, and children suffer multiple reinfections by the same viral strain, failing to develop protective memory responses. Although the generation of RSV-specific antibodies can be detected upon infection, their relevance in protection has not been conclusively determined. 
INTRODUCTION
Respiratory syncytial virus (RSV) is the leading cause of lower respiratory tract infection in infants, responsible for about three million hospitalizations and 66,000 deaths every year in children under two years of age (1) . RSV-infected infants develop upper respiratory tract symptoms, often progressing to bronchiolitis and/or pneumonia, and even respiratory failure, which frequently needs mechanical ventilation and intensive care unit therapy (2) . There is no effective vaccine available against RSV, and passive immunization with monoclonal antibodies is used only in high risk infants, in which RSV infection can be deadly. However, it is not only in premature children that RSV infection may be problematic or deadly; infants, elderly and pregnant women are also target populations (3), reinforcing the need for development of an effective vaccine .
In humans, neutralizing RSV-specifics antibodies are formed in upper respiratory tract, however, re-infection with the same RSV strain is frequent in healthy, immune competent individuals (4, 5) . The protective relevance of serum antibody levels remains unclear (6, 7) . Serum antibody response was loosely correlated with protection; however, there was a correlation of nasal preexisting RSV-specific humoral response with resistance to re-infection (8) . Other studies have correlated the presence of serum high avidity RSV-specific IgG with protection (9); although these antibodies have a short life in children (10) and adults (11) . Nevertheless, RSV morbidity and mortality are mainly associated with 2-4 months of age infants when titers of maternal antibodies are decreasing and have not yet been replaced by an endogenous antibody responses (12) . In mice, the RSV antibody response induced by formalin-inactivated RSV (FI-RSV) is non-protective (13) . Formalin inactivation results in conformational changes of the RSV fusion protein (14) , which is required for the generation of effective neutralizing antibody responses (15) . Moreover, antibodies induced by FI-RSV are low affinity due to poor toll-like receptor (TLR) stimulation (16) .
Effective B cells responses require help from follicular helper T (TFH) cells. TFH cells are predominantly found in germinal centers (GC) of secondary lymphoid organs (17) (18) (19) and produce high levels of IL-21. This cytokine is known to increase the affinity of antibodies and induce immunoglobulin class switching (20, 21) . IL-21 acts on naive B cells in conjunction with costimulatory signals to drive the differentiation of either GC B cells or plasma cells (22) . The specific provision of TFH cells derived helper signals to GC B cells is proposed to be the major driver of antibody affinity maturation (23, 24) . Vaccine design success depends of generation of long-lived antibody-secreting plasma cells and a robust GC response (25) .
We hypothesized that RSV modulates TFH cells, preventing B cell help, targeting humoral immune response efficiency. Our results unravel an immunological mechanism by which RSV modulates TFH cells and GC reactions. We found that 
METHODS

Viruses and Cells
Vero cells (ATCC CCL81) were cultured in Dulbeccol's modified Eagle's medium (DMEM, Gibco-BRL) containing 10% fetal calf serum (FCS, Gibco-BRL) and gentamicin (0.08 mg/ml, NOVAFARMA), maintained at 37°C with 5% of CO2 and used to propagate RSV A2 strain and HSV-1 KOS strain. Viral plaque-forming units (PFU) were identified using an RSV F protein-specific antibody (Millipore, Billerica, MA, USA). Lytic plaques assay was used to calculate PFU of HSV-1. Inactivation of the viruses was performed at UV light for 30 min, at room temperature.
Animals
Female BALB/c mice ranging from 6 to 8 weeks old were purchased from the Biological Center of Experimental Models (CEMBE) of PUCRS. Mice were housed in CEMBE facility with water and food ad libitum. All animal procedures were performed in accordance with the guidelines of the Federation of Brazilian Societies for Experimental Biology and approved by the Ethics Committee for the Use of Animals of PUCRS (CEUA-PUCRS; protocol number #13/00341).
Infection and treatment
For in vitro infection, splenocytes were isolated after lysis of red blood cells. Cells were seeded at 5x10 5 cells per well in a 96 well-plate and were stimulated either with 10 2 PFU/ml of HSV-1 or RSV or the same virus inactivated by UV for 30 min. As negative controls, uninfected Vero cells were used and processed similarly to RSV infected cells. Alternatively, cells were treated with 0.5 µg of anti-PD-L1 antibody (clone MHI5, eBioscience) or control IgG (BioXcell) 1 hour before infection. The supernatant was collected at 12, 24, 48, 72 and 96 hours post-infection for analysis.
After four days, cells were labeled with specific antibodies and analyzed by flow cytometry.
For sorting, splenocytes were isolated after lysis of red blood cells and stained with specific antibodies for DCs (CD11c + CD19 -), B cells (CD19 + CD11c) and TFH cells (CD4 + CXCR5 + ). Cells were co-cultured (5x10 3 DCs, 3x10 4 TFH cells or 5x10 4 For the quantification of IgG RSV specific antibodies on mice serum, 96-well plates were sensitized overnight with RSV F protein (Sino Biological Inc.), blocked for 1 hour with blotto (5% milk, 0.05% tween in PBS 1X buffer) and serum was added in dilutions of 1/10, 1/100, 1/500, 1/1000, 1/5000 and incubated for 2 hours at room temperature. Rabbit anti-mouse antibody HRP-conjugated (Invitrogen) and TMB (Life Technologies) was used to development. Plates were read at 450nm in EZ Read 400
Microplate reader (Biochrom).
ELISA to measure the avidity of anti-RSV antibody was conducted in the same manner, however the plate was washed with a 6M Urea solution. The results were expressed as an Avidity Index (AI), which was calculated as previously described by Freitas et al (9) . The avidity of RSV-specific total IgG was classified according to values that had been predetermined arbitrarily defined as low (<50%), intermediate (50-70%), or high (>70%).
Neutralization assay
Antibody neutralization capacity assay was performed as previously described by Zielinska et al (26) , with modifications. Four-fold serial dilutions from 1:10 to 1:10240 were prepared in virus diluent (DMEM 0% FCS and 1% gentamicin (0.08 mg/ml, NOVAFARMA). Serially diluted serum was challenged with an equal volume of the RSV-A2 strain, previously tittered to give ~150 PFU per 50 µl of inoculum. The serum/virus mixtures were incubated at 37°C, 5% CO2 for 1 h. 
Histology and Immunohistochemistry
Lungs and spleens were fixed with 10% formalin, embedded in paraffin and cut into 5 μm-thick sections. Hematoxylin and eosin staining was performed in slide sections to evaluated inflammation scores. For immunohistochemistry, slides sections were deparaffinized with xylol and endogenous peroxidase activity was blocked by incubation with 3% H2O2 in methanol. Antigen unmask was performed by incubating the slides in 0.1 mol/L citrate buffer, pH 6, for 30 min at 95°C, followed by cooling at room temperature for 1h. Sections were blocked in PBS with 4% bovine serum albumin (BSA), 5% mouse serum, and incubated with primary antibody anti-PD-L1 (clone MIH5, eBioscience) at 1:1000 dilution in PBS, 1% BSA, and 1.25% mouse serum. Biotinylated goat-derived secondary antibodies were detected by the avidinbiotin-horseradish peroxidase complex method (Dako Systems) using 3,3-diaminobenzidine-tetrahydrochloride (Sigma-Aldrich) as a substrate.
Real Time-PCR
Total RNA was extracted from the lungs of infected animals using Viral RNA/DNA Mini Kit (PureLink® -Invitrogen) following manufacturer's instructions. cDNA was synthesized with random primers using Sensiscript® Reverse Transcription kit (QIAGEN®). The quality of cDNA for each sample was tested by amplification of the endogenous β-actin gene using specific primers from TaqMan Assay (Applied Biosystems). Samples that did not amplify for β-actin were excluded. Real-time PCR was performed for the amplification of the RSV F protein gene using the primers and specific probes (forward-5'-AACAGATGTAAGCAGCTCCGTTATC-3 ', reverse-5'-GATTTTTATTGGATGCTGTACATTT- 3 'and probe 5'-FAM / TGCCATAGCATGACACAATGGCTCCT-TAMRA / -3'). For standard curve a ten-fold serial dilutions of 6x10 7 copies of a plasmid with RSV F protein sequence were added to the same plate of qPCR in duplicate. The results were measured by
StepOne™ Real-Time PCR System (Applied Biosystems) and used for further quantification of the samples viral load.
Passive immunization
Mice were separated into 3 groups, the first group received naive IgG serum, the second group received IgG serum from RSV-infected mouse and the latter group received IgG serum from RSV-infected and IL-21 treated mouse. For IgG purification was used Protein A-Sepharose column (Sigma) following manufacturer's instructions.
Each mouse received intraperitoneal 300µg of purified IgG. After two days, animals were infected with 10 7 PFU of RSV. Mice were euthanized at day 5 post-infection and lungs were harvesedt for further analysis.
Statistical analysis
The significance for differences between the groups was analyzed with one-way ANOVA test followed by a Bonferroni post-test or t-test were applied to parametric data using GraphPad Prism software (San Diego, CA, USA). Values demonstrated in graphs are mean and standard deviation (S.D.) and a level of significance of p < 0.05 was established for the analyses.
RESULTS
RSV induces TFH proliferation in vitro.
Given the importance of TFH cells in helping B cells to produce antibodies, we analyzed whether RSV could modulate TFH cells proliferation in vitro. Mice splenocytes were infected with 10 2 PFU/ml of HSV-1 or RSV for 4 days. HSV-1 was used as a positive control since it induces high levels of high affinity HSV-specific antibodies (27) (28) (29) . We found that both RSV and HSV-1 increase the frequency of TFH (CD3 + CD4 + CXCR5 + PD-1 + ) cells compared to uninfected controls ( 
RSV decreases the IL-21R expression in TFH and B cells and IL-21 secretion
We next investigated whether RSV could affect the function of TFH cells. Production of IL-21 is an important indicator of TFH activity (30) . IL-21 is necessary for antibody affinity maturation and B cell differentiation, and is known to upregulate the expression of its receptor on CD4 + T cells. No IL-21 production was detected when RSV was added to splenocyte cultures, in contrast to what was observed for HSV-1 ( Fig. 2A) . In vivo, IL-21 serum levels were undetectable even 4 days post-infection ( Fig. 2 B) , again contrasting to the abundant IL-21 induction observed during HSV-1 infection. RSV in vitro also reduced IL-21R expression on TFH cells (Fig. 2, C and D) and B cells (CD3 -CD19 + ) ( 
IL-21 treatment increases B cell follicle size, IgG production, antibody avidity and neutralization capacity
We hypothesized that the low levels of IL-21 observed upon RSV infection (Fig. 2 B) would lead to poor humoral responses against the virus. IL-21 is a key cytokine for humoral immune responses, however the influence of this cytokine in GC reaction and antibody avidity during RSV infection was so far unexplored. To evaluate the IL-21 action in RSV infection in vivo, we infected mice with RSV and treated them with recombinant, endotoxin-free IL-21 (Supplementary figure 2) . Accordingly, we observed that animals infected with RSV showed undeveloped B cell follicles in the spleen (Fig. 3 A) , differently from HSV-1 infected mice, which presented greatly augmented follicles compared to uninfected controls. This was reversed by IL-21 treatment. IL-21 treatment led to increase in sizes of splenic B cell follicles during RSV infection (Fig. 3 A) . IL-21 treatment also increased the frequencies of B and TFH cells (Fig 3B and C) . Finally, treatment with IL-21 also improved titers (Fig. 3 D) , avidity ( Fig. 3 E) , and neutralization capacity (Fig. 3 F) of anti-F protein specific antibodies.
IL-21 treatment protects RSV infected animals and decreases lung inflammation by specific humoral immune response
To evaluate the protective roles of IL-21 in vivo, the same experimental design was performing (Supplementary figure 2) . While pulmonary injury was observed in lungs of untreated RSV-infected mice, (Fig. 4 A, with arrows showing cell infiltration and reduction of bronchi lumen space), treatment with IL-21 reduced inflammation as well as improved survival compared to non-treated infected mice, reducing weight loss in infected animals (Fig. 4 B and C) . IL-21 treatment also decreases numbers of RSV copies in lungs in RSV-infected mice (Fig. 4 D) . These results suggest that IL-21 is essential for protection from RSV infection by modulating TFH and B cells function.
To further investigate the immunologic mechanisms of protection, we pretreated (two The prediction from our hypothesis was that PD-L1 blockade could recover the ability of TFH cells to produce IL-21 in the presence of RSV. To test that, we blocked PD-L1
in vitro, and infected mouse splenocytes with 10 2 PFU/ml of RSV for 4 days. Blocking PD-L1 increased IL-21 production by RSV-infected cells, as measured by ELISA (Fig. 5 D) . Two days post-infection, IL-21 levels began to decrease in supernatants.
At 96h post-infection, PD-L1 blockade significantly restored IL-21 secretion (Fig. 5 B) .
In sorted cells, PD-L1 blockade also recovered IL-21R expression on B cells ( 
DISCUSSION
In this study, we unveil a mechanism by which RSV can evade effector immune responses, interfering with TFH cells function, and consequently impairing the generation of protective antibodies. When we blocked PD-L1 in vitro during RSV infection, IL-21 secretion was increased.
Recent studies report that impairing TFH differentiation and/or function is an important virulence mechanism for different viruses. Lymphocytic choriomeningitis virus (LCMV) negatively modulates antibody responses by killing TFH cells via NK cells cytotoxicity (34). HIV infection induces TFH cells proliferation, however recruits these cells to work as a subclinical virus reservoir during antiretroviral therapy (ART) (35). In addition, HIV infection is associated with decrease of T follicular regulatory cells (TFR) function, leading to TFH cells proliferation and increase of viral replication (36). This might be one of the reasons why HIV humoral immune responses
Our results agree with Zhou et al who observed that IL-21 serum levels were inversely correlated with the high intensity of tumor PD-L1 expression in patients with hepatocarcinoma (61) . A previous study demonstrated that PD-L1 expression on lung DCs controls inflammation, and anti-PD-L1 treatment of RSV-infected animals induced pro-inflammatory cytokines, exacerbating pulmonary inflammation and host disease (54) . In that study, they found only a moderate enhancement of TFH cells numbers, and no improvement of antibody responses, at day 6 after infection (54).
However, we found a significant increase in serum RSV-specific antibodies at day 14 post-infection in mice treated with IL-21, but not at day 6 as described by Yao et al.
Thus, we believe that the benefit of anti-PD-L1 treatment on RSV antibody response could be overridden by the lung inflammation it would induce -and an early course of Il-21 therapy might constitute an interesting approach to circumvent the TFH cell function impairment that ensues upon RSV infection. 
